Life Science Investment Community Survey: Assessing COVID-19 Disclosure Expectations and Implications
As we move past the initial panic and any off-cycle business impact announcements related to COVID-19, companies are at a critical inflection point as they prepare for first quarter earnings and adjust full year investor relations planning. With a somewhat clearer understanding of the near-term business impact of the virus juxtaposed with the uncertainty around timelines and longer-term consequences, companies are in a difficult position of trying to maintain transparency with investors looking for directional updates around key value drivers without much of the information currently in hand.
With investor conferences going virtual and non-deal roadshows halted, what does a proper investor engagement strategy look like in this COVID-19 era? Further, how should management teams communicate to the Street with no understanding of timelines and full economic impact from the virus?
To help assess current capital markets expectations and provide more context around COVID-19 impact and best practices, FTI surveyed select members of the Life Sciences investment community to ascertain insights.
